共 48 条
- [41] Prognosis in patients with advanced pancreatic cancer and effectiveness of 1st-line treatments - a prognostic and comparative effectiveness study using propensity score weighting for patients treated with Gem plus Nab vs. FOLFIRINOX from the TPK registry ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 213 - 213
- [45] Intraoperative Teilbrustbestrahlung mit Elektronen (ELIOT) vs. konventionelle Ganzbrustbestrahlung beim invasiven Mammakarzinom im frühen Stadium nach brusterhaltender Operation: Langzeitdaten einer kontrollierten, randomisierten StudieIntraoperative partial breast irradiation with electrons (ELIOT) compared to conventionally fractionated whole-breast irradiation of early-stage invasive breast cancer after breast-conserving surgery: long-term data from a prospective randomised trial Strahlentherapie und Onkologie, 2021, 197 (11) : 1032 - 1036
- [46] Five year median follow-up data from a prospective, randomized, placebo-controlled, single-blinded, multicenter, phase IIb study evaluating the reduction of recurrences using HER2/neu peptide GP2+GM-CSF vs. GM-CSF alone after adjuvant trastuzumab in HER2 positive women with operable breast cancer CANCER RESEARCH, 2021, 81 (04)
- [47] Final five-year median follow-up safety data from a prospective, randomized, placebo-controlled, single-blinded, multicenter, phase IIb study evaluating the use of HER2/neu peptide GP2+GMCSF vs. GM-CSF alone after adjuvant trastuzumab in HER2-positive women with operable breast cancer. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
- [48] Final five year median follow-up data from a prospective, randomized, placebo-controlled, single-blinded, multicenter, phase IIb study evaluating a time series of immune responses using HER2/neu peptide GP2+GM-CSF vs. GM-CSF alone after adjuvant trastuzumab in HER2 positive women with operable breast cancer. CANCER RESEARCH, 2021, 81 (13)